Bibliographic review on the relationship between endometrial cancer and pelvic floor dysfunction

This Narrative review examines the relationship between endometrial cancer (EC) and pelvic floor dysfunction (PFD), which includes urinary and fecal incontinence, pelvic organ prolapse, and related treatment needs. A comprehensive search of medical databases and peer-reviewed journals was carried out to identify studies published from 2010 to 2025, focusing on the latest evidence. While oncologic outcomes for EC have improved thanks to advances in diagnosis, molecular classification and treatment, the effect of EC and its therapies on pelvic floor health is still not fully addressed in clinical practice. This review shows that PFD is highly prevalent in EC survivors and highlights the importance of early detection, patient education, personalized rehabilitation and good teamwork among specialists. Future research should clarify the long-term impact of EC treatments on pelvic floor function and look for innovative tools, such as biomarkers like microRNAs, to support prevention and tailored care. Integrating pelvic floor health into follow-up plans can help protect function and improve quality of life for women after EC.

Endometrial cancer; Pelvic floor disorders; Pelvic floor dysfunction; Urinary incontinence; Fecal incontinence; Pelvic organ prolapse

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016; 387: 1094–1108.

[3] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022; 72: 7–33.

[4] Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology. 1983; 15: 10–17.

[5] Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.

[6] Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer. 2021; 31: 12–39.

[7] Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. International Journal of Gynecological Cancer. 2016; 26: 2–30.

[8] Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Annals of Oncology. 2015; 26: 1635–1648.

[9] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022; 399: 1412–1428.

[10] Ryan NAJ, Glaire MA, Blake D, Cabrera-Dandy M, Evans DG, Crosbie EJ. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genetics in Medicine. 2019; 21: 2167–2180.

[11] Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia: ACOG clinical consensus No. 5. Obstetrics & Gynecology. 2023; 142: 735–744.

[12] Shikeli S, Gowri V, Rawahi TA. Fertility-sparing treatment in young women with atypical endometrial hyperplasia and low-grade endometrial cancer: a tertiary center experience. JBRA Assisted Reproduction. 2020; 24: 466–469.

[13] Koskas M, Uzan J, Luton D, Rouzier R, Daraï E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertility and Sterility. 2014; 101: 785–794.

[14] Raffone A, Travaglino A, Mascolo M, Carbone L, Guida M, Insabato L, et al. TCGA molecular groups of endometrial cancer: pooled data about prognosis. Gynecologic Oncology. 2019; 155: 374–383.

[15] Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2020; 76: 52–63.

[16] Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. The Lancet Oncology. 2014; 15: e268–e278.

[17] Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nature Reviews Cancer. 2019; 19: 510–521.

[18] Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecologic Oncology Research and Practice. 2017; 4: 19.

[19] Ye AL, Johnston E, Hwang S. Pelvic floor therapy and initial interventions for pelvic floor dysfunction in gynecologic malignancies. Current Oncology Reports. 2024; 26: 212–220.

[20] Ramaseshan AS, Felton J, Roque D, Rao G, Shipper AG, Sanses TVD. Pelvic floor disorders in women with gynecologic malignancies: a systematic review. International Urogynecology Journal. 2018; 29: 459–476.

[21] Faubion SS, Shuster LT, Bharucha AE. Recognition and management of nonrelaxing pelvic floor dysfunction. Mayo Clinic Proceedings. 2012; 87: 187–193.

[22] Puntambekar S, Manchanda R. Surgical pelvic anatomy in gynecologic oncology. International Journal of Gynecology & Obstetrics. 2018; 143: 86–92.

[23] Kalampokas E, Giannis G, Kalampokas T, Papathanasiou AA, Mitsopoulou D, Tsironi E, et al. Current approaches to the management of patients with endometrial cancer. Cancers. 2022; 14: 4500.

[24] Terzic M, Aimagambetova G, Kunz J, Bapayeva G, Aitbayeva B, Terzic S, et al. Molecular basis of endometriosis and endometrial cancer: current knowledge and future perspectives. International Journal of Molecular Sciences. 2021; 22: 9274.

[25] Pelvic organ prolapse: ACOG practice bulletin, number 214. Obstetrics & Gynecology. 2019; 134: e126–e142.

[26] Bernard S, Moffet H, Plante M, Ouellet MP, Leblond J, Dumoulin C. Pelvic-floor properties in women reporting urinary incontinence after surgery and radiotherapy for endometrial cancer. Physical Therapy. 2017; 97: 438–448.

[27] Peinado-Molina RA, Hernández-Martínez A, Martínez-Vázquez S, Rodríguez-Almagro J, Martínez-Galiano JM. Pelvic floor dysfunction: prevalence and associated factors. BMC Public Health. 2023; 23: 2005.

[28] Cai L, Wu Y, Xu X, Cao J, Li D. Pelvic floor dysfunction in gynecologic cancer survivors. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2023; 288: 108–113.

[29] Sadri H, Oliaei A, Sadri S, Pezeshki P, Chughtai B, Elterman D. Systematic review and meta-analysis of urinary incontinence prevalence and population estimates. Neurourology and Urodynamics. 2024; 43: 52–62.

[30] Yang EJ, Lim JY, Rah UW, Kim YB. Effect of a Pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: a randomized controlled trial. Gynecologic Oncology. 2012; 125: 705–711.

[31] Maturen KE, Martin MF, Chapman CH, McLean K, Michaels BN, Uppal S, et al. Pelvic recovery after endometrial cancer treatment: patient-reported outcomes and MRI findings. Academic Radiology. 2023; 30: S202–S210.

[32] Segal S, John G, Sammel M, Andy UU, Chu C, Arya LA, et al. Urinary incontinence and other pelvic floor disorders after radiation therapy in endometrial cancer survivors. Maturitas. 2017; 105: 83–88.

[33] Erkılınç S, Çakır I, Karataşlı V, Can B, Ata C, Avşar A, et al. Radiotherapy improves stress urinary incontinence but impairs pelvic floor function in endometrial cancer patients: a prospective cohort study. Archives of Gynecology and Obstetrics. 2025; 311: 1133–1139.

[34] Theodoulidis I, Mikos T, Tsolakidis D, Zepiridis L, Grimbizis GF. Pelvic floor dysfunction in endometrial cancer patients after treatment: a literature review. European Journal of Gynaecological Oncology. 2022; 43: 132–142.

[35] Haylen BT, Maher CF, Barber MD, Camargo S, Dandolu V, Digesu A, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP). International Urogynecology Journal. 2016; 27: 165–194.

[36] Pizzoferrato AC, Klein M, Fauvet R, Durand C, Foucher F, Sardain H, et al. Pelvic floor disorders and sexuality in women with ovarian cancer: a systematic review. Gynecologic Oncology. 2021; 161: 264–274.

[37] Lukacz ES, Whitcomb EL, Lawrence JM, Nager CW, Contreras R, Luber KM. Are sexual activity and satisfaction affected by pelvic floor disorders? Analysis of a community-based survey. American Journal of Obstetrics & Gynecology. 2007; 197: 88.

[38] Vargas Maldonado D, Madsen AM. Vaginal symptoms in women who are affected by gynecologic cancer. Current Opinion in Obstetrics and Gynecology. 2021; 33: 474–482.

[39] Neron M, Bastide S, Tayrac R, Masia F, Ferrer C, Labaki M, et al. Impact of gynecologic cancer on pelvic floor disorder symptoms and quality of life: an observational study. Scientific Reports. 2019; 9: 2250.

[40] Lipetskaia L, Sharma S, Johnson MS, Ostergard DR, Francis S. Urinary incontinence and quality of life in endometrial cancer patients after robotic-assisted laparoscopic hysterectomy with lymph node dissection. Journal of Obstetrics and Gynaecology. 2019; 39: 986–990.

[41] Tunn R, Baessler K, Knüpfer S, Hampel C. Urinary incontinence and pelvic organ prolapse in women. Deutsches Ärzteblatt International. 2023; 120: 71–80.

[42] Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017; 318: 1592–1604.

[43] Wu JM. Stress incontinence in women. The New England Journal of Medicine. 2021; 384: 2428–2436.

[44] Mazur-Bialy AI, Kołomańska-Bogucka D, Opławski M, Tim S. Physiotherapy for prevention and treatment of fecal incontinence in women—systematic review of methods. Journal of Clinical Medicine. 2020; 9: 3255.

[45] Sung VW, Rogers RG, Bann CM, Arya L, Barber MD, Lowder J, et al. Symptom outcomes important to women with anal incontinence: a conceptual framework. Obstetrics & Gynecology. 2014; 123: 1023–1030.

[46] Dumoulin C, Hay-Smith J, Habée-Séguin GM, Mercier J. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women: a short version Cochrane systematic review with meta-analysis. Neurourology and Urodynamics. 2015; 34: 300–308.

[47] Todhunter-Brown A, Hazelton C, Campbell P, Elders A, Hagen S, McClurg D. Conservative interventions for treating urinary incontinence in women: an overview of Cochrane systematic reviews. The Cochrane Database of Systematic Reviews. 2022; 9: CD012337.

[48] Moris L, Heesakkers J, Nitti V, O’Connell HE, Peyronnet B, Serati M, et al. Prevalence, diagnosis, and management of stress urinary incontinence in women: a collaborative review. European Urology. 2025; 87: 292–301.

[49] Hay-Smith EJC, Starzec-Proserpio M, Moller B, Aldabe D, Cacciari L, Pitangui ACR, et al. Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women. The Cochrane Database of Systematic Reviews. 2024; 12: CD009508.

[50] Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. The New England Journal of Medicine. 2009; 360: 481–490.

[51] Reilly ET, Freeman RM, Waterfield MR, Waterfield AE, Steggles P, Pedlar F. Prevention of postpartum stress incontinence in primigravidae with increased bladder neck mobility: a randomised controlled trial of antenatal pelvic floor exercises. BJOG. 2002; 109: 68–76.

[52] Hao J, Yao Z, Remis A, Huang B, Li Y, Yu X. Pelvic floor muscle training in telerehabilitation: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics. 2024; 309: 1753–1764.

[53] Lakomy DS, Yoder AK, Wu J, Hernandez M, Ayoola-Adeola M, Jhingran A, et al. Impact of treatment modality on pelvic floor dysfunction among uterine cancer survivors. 2022. Available at: https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(24)00689-3/pdf (Accessed: 24 July 2025).

[54] Robison K, Wohlrab K, Howe CJ, Richter HE, Sung V, Bevis KS, et al. Endometrial cancer surgery with or without concomitant stress urinary incontinence surgery. Obstetrics & Gynecology. 2023; 141: 642–652.

[55] Di Fiore R, Suleiman S, Pentimalli F, O’Toole SA, O’Leary JJ, Ward MP, et al. Could microRNAs be useful tools to improve the diagnosis and treatment of rare gynecological cancers? A brief overview. International Journal of Molecular Sciences. 2021; 22: 3822.

[56] Brennen R, Lin KY, Denehy L, Soh SE, Jobling T, McNally OM, et al. Natural history of pelvic floor disorders before and after hysterectomy for gynaecological cancer. BJOG. 2024; 131: 1545–1554.

[57] Hu JS, Pierre EF. Urinary incontinence in women: evaluation and management. American Family Physician. 2019; 100: 339–348.

[58] Navarro Brazález B, Torres Lacomba M, de la Villa P, Sánchez Sánchez B, Prieto Gómez V, Asúnsolo Del Barco Á, et al. The evaluation of pelvic floor muscle strength in women with pelvic floor dysfunction: a reliability and correlation study. Neurourology and Urodynamics. 2018; 37: 269–277.

[59] Bø K, Sherburn M. Evaluation of female pelvic-floor muscle function and strength. Physical Therapy. 2005; 85: 269–282.

[60] Cyr MP, Jones T, Brennen R, Colombage U, Frawley HC. Effectiveness of pelvic floor muscle and education-based therapies on bladder, bowel, vaginal, sexual, psychological function, quality of life, and pelvic floor muscle function in females treated for gynecological cancer: a systematic review. Current Oncology Reports. 2024; 26: 1293–1320.